Hirono Otomaru

Dr. Hirono Otomaru

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2026 in Pathogens
Verified
Journal Article
Open access
PDF file
Stephen Anyona OmaeStephen Anyona Omae
Stephen Anyona Omae
MSMohammad Monir Shah
Mohammad Monir Shah
HNHien-Anh Thi Nguyen
Hien-Anh Thi Nguyen
KHKim-Mai Huynh
Kim-Mai Huynh
NANatsuki Ariyoshi
Natsuki Ariyoshi
LYLay Myint Yoshida
Lay Myint Yoshida
Staphylococcus aureus (S. aureus), especially Methicillin-resistant Staphylococcus aureus (MRSA), remains a major public health concern both in hospital and community settings. The MRSA carriage situation among schoolchildren in Vietnam is limited. A cross-sectional study was conducted in March 2023 to assess the prevalence, antimicrobial resistance patterns, and molecular characteristics of MRSA among schoolchildren in Nha Trang, Vietnam. Schoolchildren from grades 1 to 12 (ages 6–18 yrs) were enrolled. Background epidemiological data and nasal swabs were collected. Nasal samples were processed at the Pasteur Institute in Nha Trang, Vietnam, for S. aureus culture. Out of 1210 participants enrolled, S. aureus prevalence was 18.3% (222/1210), of which 41% (91/222) were MRSA. Primary school children showed the highest prevalence of MRSA colonization (48%), 32.8% in secondary, and 27.8% in high school. Among MRSA isolates, high levels of resistance were detected against trimethoprim-sulfamethoxazole (100%), erythromycin (68.2%) and clindamycin (45.1%). Multidrug resistance (MDR) occurred in 30% (27/90) of MRSA isolates. Staphylococcal cassette chromosome mec (SCCmec) subtype IVa was dominant (66.0%), followed by type IV (7.0%) and type V (6.0%). MLST data revealed genetic diversity whereby ST45 dominated, followed by ST546 and ST188. Continuous MRSA surveillance is essential to monitor emerging strains in the communities.

20 January 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
OAOludare ADEWUYI
Oludare ADEWUYI
MBMuhammad Shakir Balogun
Muhammad Shakir Balogun
HOHirono Otomaru
Hirono Otomaru
AAAlash'le Abimiku
Alash'le Abimiku
AAAnthony Agbakizu Ahumibe
Anthony Agbakizu Ahumibe
LYLay Myint Yoshida
Lay Myint Yoshida
Information on circulating HBV (sub-)genotype, variants, and hepatitis D virus (HDV) coinfection, which vary by geographical area, is crucial for the efficient control and management of HBV. We investigated the genomic characteristics of HBV (with a prevalence of 8.1%) and the prevalence of HDV in Nigeria. We utilised 777 HBV-positive samples and epidemiological data from the two-stage sampled population-based, nationally representative Nigeria HIV/AIDS Indicator and Impact Survey conducted in 2018. We assessed 732 HBV DNA-extracted samples with detectable viral loads (VLs) for (sub-)genotypes and variants by whole-genome pre-amplification, nested PCR of the s-and pol-gene, and BigDye Terminator sequencing. We conducted HDV serology. In total, 19 out of the 36 + 1 states in Nigeria had a high prevalence of HBV (≥8%), with the highest prevalence (10.4%) in the north-central geopolitical zone. Up to 33.2% (95% CI 30.0–36.6) of the participants had detectable VLs of ≥300 copies/mL. The predominant circulating HBV genotype was E with 98.4% (95% CI 97.1–99.1), followed by A with 1.6% (95% CI 0.9–2.9). Drug-resistant associated variants and immune escape variants were detected in 9.3% and 0.4%, respectively. The seroprevalence of HDV was 7.34% (95% CI 5.5–9.2). Nigeria has subtype E as the major genotype with many variants.

26 February 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
HOHirono Otomaru
Hirono Otomaru
YKYurika Kawazoe
Yurika Kawazoe
HNHien Anh Thi Nguyen
Hien Anh Thi Nguyen
HVHien Minh Vo
Hien Minh Vo
HLHoang Huy Le
Hoang Huy Le
LYLay Myint Yoshida
Lay Myint Yoshida
Background: Enterovirus D68 (EVD68) causes respiratory disease, yet the risk of severe respiratory disease remains incompletely quantified, especially when stratified by comorbidity status. This study aims to describe the clinical features and risk of severe disease in children with EVD68 compared with those with other Rhinoviruses/Enteroviruses, accounting for comorbidity. Methods: We analyzed 1100 pediatric EV-positive cases from surveillance in Vietnam (2019–2022), excluding viral coinfections. EVD68 was confirmed by real-time PCR. We examined clinical features, treatments, and comorbidities. Standardization methods estimated risk differences (RDs) and risk ratios (RRs) stratified by (1) general comorbidity, (2) asthma, and (3) either of these. Time-to-recovery in intensive care unit (ICU) was compared using Kaplan–Meier methods. Results: EVD68 was detected in 55/1100 cases (5.0%). Children with EVD68 more often had wheeze, pneumonia, oxygen therapy, and ICU admission. For wheeze, EVD68 was associated with similar elevated risk with and without general comorbidity (RR 1.40 in both; RD 0.27). Pneumonia risk was likewise elevated with EVD68 (with comorbidity: RR 1.17; RD 0.12; without: RR 1.73; RD 0.14). By asthma status, EVD68 increased wheeze risk in both groups; however, the excess was smaller in asthma (RR 1.10; RD 0.09) than non-asthma (RR 1.43; RD 0.29), consistent with baseline wheeze susceptibility in asthma. Pneumonia risk was similar regardless of asthma status. During ICU stay, wheeze persisted longest in both groups. Time-to-recovery was similar between groups. Conclusions: EVD68 infection was associated with a higher risk of severe disease than Rhinoviruses/Enteroviruses, independent of documented comorbidity, indicating substantial risk even among previously healthy children.

11 September 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
MTMichiko Toizumi
Michiko Toizumi
YYYutaro Yamagata
Yutaro Yamagata
HNHien Anh Thi Nguyen
Hien Anh Thi Nguyen
HOHirono Otomaru
Hirono Otomaru
HLHoang Huy Le
Hoang Huy Le
LYLay Myint Yoshida
Lay Myint Yoshida
Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in children, particularly severe during infancy. Maternal RSV-specific neutralizing antibodies (nAbs), transferred via the placenta, may provide protection in early infancy, but the extent and duration of protection remain uncertain. Objective: We investigated the association between cord blood RSV-A nAb levels and the risk of hospitalization due to RSV-associated acute respiratory infection (RSV-ARI) by 24 months of age. Methods: We conducted a case–cohort study nested within a birth cohort in Nha Trang, Vietnam. From the full cohort (n = 1977), a random subcohort of 392 infants and all 66 infants hospitalized for RSV-ARI by age 24 months were included for RSV-A nAb testing. RSV-A nAb titers at birth were categorized into three groups in the subcohort (low: lowest quartile; middle; interquartile; high: highest quartile). Weighted Cox proportional hazards regression was used to estimate hazard ratios (HRs) for RSV-ARI hospitalization. Results: The incidence of RSV-ARI hospitalization was 17.92 per 1000 person-years by 24 months, and 25.40 per 1000 person-years among infants aged <12 months. Among infants aged <6 months, those in the low nAb group had a significantly higher risk of hospitalization compared to the middle nAb group (adjusted HR: 4.05; 95% CI: 1.51–10.89). Maternal anemia was consistently associated with increased risk. Conclusions: Lower RSV-nAb titers at birth were associated with an increased risk of RSV-ARI hospitalization during early infancy. These findings support the importance of maternal immunization strategies to enhance infant protection against RSV.